Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Orelabrutinib in Primary Progressive Multiple Sclerosis
2025-524316-11-00Phase 3Authorised
- Sponsor
- Zenas BioPharma
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 33
01
Overview
Phase 3, randomised, double-blind trial in primary progressive multiple sclerosis (PPMS) comparing Orelabrutinib with Placebo (2 arms). Primary endpoint: Time to onset of 12-week confirmed composite disability progression (cCDP). Planned start Jun 2026; status: authorised.
02
Drugs
orelabrutinib
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on 2025-524316-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524316-11-00.